Cambridge Investment Research Advisors
HELP

Cambridge Investment Research Advisors’s Helus Pharma Inc. Common Stock HELP Stock Holding History

Cambridge Investment Research Advisors’s Portfolio HELP Stock Details HELP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-264
Closed -$6K – 3082
2022
Q2 		$6K Buy
+264
New +$6.4K ﹤0.01% 3028
2022
Q1 		– Sell
-441
Closed -$20K – 3190
2021
Q4 		$20K Buy
+441
New +$27.9K ﹤0.01% 3132

Other funds holding HELP

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return
IWP
IAG Wealth Partners Waukesha, Wisconsin $1.01B AUM 17.58% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Cambridge Investment Research Advisors's HELP Position: Q3 2022 in Review

Cambridge Investment Research Advisors sold out of Helus Pharma Inc. Common Stock (HELP) in Q3 2022, closing a stake of 264 shares — an estimated $6K sold.

Cambridge Investment Research Advisors first reported a position in HELP in Q4 2021 and held it in 2 quarters. The position peaked at $20K in Q4 2021. 61 funds tracked by Wall St. Rank hold HELP as of Q3 2022.

  • Cambridge Investment Research Advisors reported no remaining Helus Pharma Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 264 Helus Pharma Inc. Common Stock shares in Q3 2022, an estimated $6K.
  • Cambridge Investment Research Advisors first reported a position in Helus Pharma Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • Cambridge Investment Research Advisors's Helus Pharma Inc. Common Stock position peaked at $20K in Q4 2021.
  • 61 funds tracked by Wall St. Rank held Helus Pharma Inc. Common Stock as of Q3 2022.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2022, filed 17 Oct 2022.